Teva Reports Laquinimod Phase IIa trial positive results

Teva Pharmaceutical Industries and Active Biotech have presented positive data from Phase IIa trial designed to evaluate the safety and efficacy of laquinimod in patients with moderate to severe active Crohn’s disease (CD).

According to the study data, the of laquinimod 0.5mg/day exhibitted the steady effect on and response rates in patients with moderate-to-severe CD versus placebo.
Review
and Active Biotech have presented positive data from Phase IIa trial designed to evaluate the safety and efficacy of laquinimod in patients with moderate to severe active Crohn’s disease (CD). According to the study data
Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in PharmaLive.com ()all 5 news articles »

Leave a Reply